Esperion Secures Patent Protection for NEXLETOL Until 2040 Through Settlement with Micro Labs
• Esperion Therapeutics has reached a settlement agreement with Micro Labs that prevents the generic manufacturer from marketing a version of NEXLETOL (bempedoic acid) before April 19, 2040.
• The agreement resolves patent litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application seeking approval for a generic version of the cholesterol-lowering medication.
• Litigation against eight other ANDA filers continues, with no guarantee that these ongoing cases will prevent other generic versions from entering the market before the 2040 patent expiration.
NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry
• India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin.
• The price regulations follow the March 11, 2025 expiry of Boehringer Ingelheim's empagliflozin patent, opening the market to multiple pharmaceutical companies including Mankind Pharma, Lupin, and Alkem Laboratories.
• Beyond diabetes medications, the NPPA's pricing decisions also cover anti-hypertensive combinations containing telmisartan and metoprolol, as well as anti-inflammatory formulations with paracetamol and mefenamic acid.
Allchem Lifescience Files for IPO to Raise ₹190 Crore, Expands API Manufacturing Capabilities
• Gujarat-based Allchem Lifescience has filed preliminary IPO papers with SEBI, seeking to raise ₹190 crore through fresh equity shares and an offer for sale of 71.55 lakh shares by promoters.
• The company specializes in manufacturing API intermediates and piperazine derivatives critical for drugs like quetiapine, with ₹130 crore of proceeds earmarked for debt repayment.
• Allchem has demonstrated strong financial growth with revenue CAGR of 12.75% and profit CAGR of 28.65% between FY22-24, serving 214 customers across 22 countries globally.
© Copyright 2025. All Rights Reserved by MedPath